SB240683: Phase I data; Phase I/II

In a placebo-controlled Phase I study of 24 patients with mild to moderate asthma, PDLI said that single intravenous doses of SB240683 (0.5, 1.5, 4.5 or 10 mg/kg) were well tolerated with no dose-limi...